



- Công bố khoa học và công nghệ Việt Nam
Công nghệ sinh học liên quan đến y học, y tế
Nguyễn Thị Thu Trâm(1), Le Seyec Jacques, Tống Hồ Đạt, Trương Hoài Phong, Lohézic-Le Dévéhat Françoise, Vu Thi Huyen
Khảo sát khả năng ức chế virus viêm gan C của các hợp chất cô lập từ loài địa y Parmotrema tinctorum (Nyl.) Hale
Study on anti-hepatitis C virus activity of the isolated compounds from lichen Parmotrema tinctorum (Nyl.) Hale
Khoa học (Đại học Cần Thơ)
2020
1A
69-74
1859-2333
TTKHCNQG, CVv 403
- [1] Thiago, I.B.L.; Roberta, G.C.; Nídia, C.Y.; Neli, H. (2008), Radical-scavenging activity of orsellinates,Chemical and Pharmaceutical Bulletin. 56(11): 1551-1554
- [2] Nguyen, T.T.T.; Nguyen, T.T.; Nguyen, P.D.; Nguyen, T.N.V.; Nguyen, P.H.T. (2016), Study on chemical constituents of the lichen Parmotrema sancti-angelii (Lynge) Hale (Parmeliaceae),Vietnam Journal of Chemistry. 54(4): 524-527
- [3] Vu, T.H.; Anne-Cécile, L.L.; Claudia, L., et al. (2015), Depsides: lichen metabolites active against Hepatitis C virus,Plos One. 10(3): 1-14
- [4] Lai, D.; Odimegwu, D.C.; Esimone, C.; Grunwald T.; Proksch, P. (2013), Phenolic compounds with in vitro activity against respiratory syncytial virus f-rom the Nigerian lichen Ramalina farinacea,Planta Medica. 79(15): 1440–1446
- [5] Zambare, V.P.; Christopher, L.P. (2012), Biopharmaceutical potential of lichens,Pharmaceutical Biology. 50(6): 778–798
- [6] Boustie, J.; Grube, M. (2005), Lichens: a promising source of bioactive secondary metabolites,Plant Genetic Resources. 3(2): 273–287
- [7] Stocker-Wörgötter, E. (2008), Metabolic diversity of lichen-forming ascomycetous fungi: culturing, polyketide and shikimate metabolite production, and PKS genes,Natural Product Reports. 25(1): 188–200
- [8] Hattori, M.; Ma, C-M.; Wei, Y.; Dine, R.S.E.; Sato, N. (2013), Survey of anti-HIV and antiHCV compounds f-rom natural sources,Canadian Chemical Transactions. 1(2): 116–140
- [9] Calland, N.; Dubuisson, J.; Rouillé, Y.; Séron, K. (2012), Hepatitis C virus and natural compounds: a new antiviral approach?,Viruses. 4(10): 2197–2217
- [10] DeLemos, A.S.; Chung R.T. (2014), Hepatitis C treatment: an incipient therapeutic revolution,Trends in Molecular Medicine, 20(6): 315–321
- [11] McHutchison, J.G.; Gordon, S.C.; Schiff, E.R., et al. (1998), Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C,The New England Journal of Medicine. 339(21): 1485–1492
- [12] Lavanchy, D. (2011), Evolving epidemiology of hepatitis C virus,Clinical Microbiololy and Infection. 17(2): 107–115